Skip to main content
. Author manuscript; available in PMC: 2021 Apr 9.
Published in final edited form as: Oncogene. 2020 Oct 9;39(49):7209–7223. doi: 10.1038/s41388-020-01493-8

Fig. 4. ‘miRNA classifier’ is robust in differentiating between CRPC-Adenocarcinoma and CRPC-NE states in validation cohorts of prostate adenocarcinomas.

Fig. 4.

A. Unsupervised principal component analyses (PCA) for validation cohort.

B. Single model prediction algorithm for ‘miRNA classifier data’ from cohort 1 as applied to NGS data for validation cohort,

C. Prediction probabilities for samples in validation cohort to be ‘adenocarcinoma’ (gray) or ‘NE’ (red) histology based on validated miRNA classifier.

D. Application of miRNA classifier to the TCGA database of primary adenocarcinomas (n = 494) [29]. Adeno vs NE prediction probabilities for individual tumors are represented.

E. Prediction probabilities for samples in Taylor et al. [30] cohort to be ‘adenocarcinoma’ (blue) or ‘NE’ (orange) histology based on subsetted miRNA classifier (represented in Fig. S6)